Skip to content
HowShorted

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2018

In 2018, BRAINSTORM CELL THERAPEUTICS INC.'s disclosed short interest ran from 5.89% of shares outstanding on 12 Jan 2018 to 5.69% on 31 Dec 2018, a change of -0.20 percentage points. The year's high was 6.81% on 13 Apr 2018 and its low 4.97% on 13 Jul 2018, averaging 5.89% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 43.06 days on 30 Apr 2018. Full history: BRAINSTORM CELL THERAPEUTICS INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for BRAINSTORM CELL THERAPEUTICS INC. in 2018

2018 in figures

Start of year
5.89% (12 Jan 2018)
End of year
5.69% (31 Dec 2018)
Change
-0.20 pp
High
6.81% (13 Apr 2018)
Low
4.97% (13 Jul 2018)
Average
5.89%
Highest days to cover
43.06 (30 Apr 2018)
SEC filings marked
4

Every report in 2018

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20185.89%9.84
31 Jan 20186.03%28.40
15 Feb 20186.60%23.39
28 Feb 20186.67%32.16
15 Mar 20186.76%26.6510-K filed
29 Mar 20186.67%26.67
13 Apr 20186.81%17.22
30 Apr 20186.68%43.06
15 May 20186.81%10.2510-Q filed
31 May 20186.45%3.75
15 Jun 20186.52%5.98
29 Jun 20185.62%8.45
13 Jul 20184.97%15.14
31 Jul 20185.00%24.7410-Q filed
15 Aug 20185.43%19.85
31 Aug 20185.36%16.15
14 Sep 20185.12%14.50
28 Sep 20185.12%27.12
15 Oct 20185.39%18.90
31 Oct 20185.44%16.6810-Q filed
15 Nov 20185.47%29.45
30 Nov 20185.45%41.54
14 Dec 20185.39%25.83
31 Dec 20185.69%12.75

See also: BRAINSTORM CELL THERAPEUTICS INC.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.